Makers of popular weedkiller ‘Roundup’ denies it can cause cancer

first_imgThe owner of a weedkiller used by thousands of people across Donegal has dismissed claims that one of its key ingredients can cause cancer after a US court ordered the pay-out of $290m to a terminally ill man.Bayer, the German owner of chemical giant Monsanto, said today that the ingredient glyphosate – used in its weedkiller Roundup – is “safe”.“Bayer is convinced that glyphosate is safe and does not cause cancer,” Bayer said. A California jury ordered Monsanto to pay nearly $290m (€253m) for failing to warn a dying groundskeeper that its weedkiller Roundup might cause cancer.Jurors unanimously found Monsanto acted with “malice” and that Roundup and the professional grade version RangerPro contributed “substantially” to Dewayne Johnson’s terminal illness.RTE reports that following eight weeks of trial proceedings, the San Francisco jury ordered Monsanto to pay $250m in punitive damages along with compensatory damages and other costs, bringing the total figure to nearly $290m.Mr Johnson, a California groundskeeper diagnosed in 2014 with non-Hodgkin’s lymphoma – a cancer that affects white blood cells – says he repeatedly used a generic form of RangerPro while working at a school in Benicia, California. The lawsuit is the first to accuse the product of causing cancer but is a harbinger of a looming wave of similar legal challenges: observers say a Monsanto defeat likely opens the door to hundreds of other claims against the company, which was recently acquired by Germany’s Bayer.The lawsuit built on the conclusions in 2015 of the International Agency for Research on Cancer, a part of the UN World Health Organisation, which classified Roundup’s main ingredient glyphosate as a probable carcinogen, causing the state of California to follow suit.Meanwhile, Environmental group Friends of the Earth said that everyone that uses Roundup should review its usage in the light of the findings of the US court.Director Oisín Coughlan said the case is a game changer and very significant.He said they have always opposed the use of the substance because of its affect on pollinators. Roundup is Monsanto’s leading product and glyphosate is reportedly the world’s most commonly used weedkiller.Monsanto always denied any link to the disease and said studies concluded the product was safe.The company’s vice president, Scott Partridge, said hundreds of studies showed the herbicide does not cause cancer and said the company would appeal the verdict to “vigorously defend this product”.He said: “Roundup has been safe for four decades and will continue to be safe. There is no credible scientific evidence that demonstrates otherwise. “It is completely and totally safe and the public should not be concerned about this verdict, it is one that we will work through the legal process to see if we can get the right result. The science is crystal clear.”In November 2017 the European Union approved the use of glyphosate for the next five years.At the time, the President of the Irish Farmers’ Association, Joe Healy, said it was an important outcome for farmers and for science.The chemical has been used by farmers for more than 40 years, but its safety was cast in doubt when a World Health Organisation agency, the International Agency for Research on Cancer (IARC), concluded in 2015 it probably causes cancer.In 2016, a joint report by the World Health Organisation and the UN said that, while there was “some evidence of a positive association between glyphosate exposure and risk of non-Hodgkin’s lymphoma” in some studies, the only large study of high quality found “no evidence of an association at any exposure level”.It concluded that glyphosate “is unlikely to pose a carcinogenic risk to humans from exposure through the diet”.Makers of popular weedkiller ‘Roundup’ denies it can cause cancer was last modified: August 14th, 2018 by StephenShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window)last_img read more

UAB professor receives award for malaria prevention study in pregnant women in

first_imgMay 25 2018Jodie Dionne-Odom, M.D., assistant professor in the University of Alabama at Birmingham’s Division of Infectious Diseases and chief of Women’s Health Services at UAB’s 1917 Clinic, has been awarded a five-year, $841,000 K23 grant from the National Institute of Child Health and Human Development of the National Institutes of Health. The award will fund a randomized controlled phase II study to determine the efficacy and safety of a new antibiotic regimen to prevent malaria and other infections during pregnancy among women living with HIV in Cameroon.Currently, more than 3 billion people are at risk of contracting malaria, and pregnant women with HIV in Africa are at heightened risk. In a resource-limited setting, Dionne-Odom’s research will hopefully find an effective prophylaxis for these patients that will improve adverse birth outcomes, improve maternal health and combat the spread of malaria in vulnerable populations.Related StoriesEngineers crack the code to quickly diagnose anti-malarial drug resistanceStudy shows how the mosquito immune system combats malaria parasitesProteasome inhibitors show potential for combating multidrug-resistant malaria”Women in sub-Saharan Africa are at a very high risk of getting malaria and having complications of pregnancy as a result of infection, and malaria and HIV are leading causes of death in Cameroon,” Dionne-Odom said. “We’re hoping to identify a successful regimen to prevent common infections in this exposed population that will in turn improve pregnancy and birth outcomes, while helping other at-risk women across the world in the future.”When pregnant women are infected with malaria, a vector-borne disease transmitted through mosquito bites, they can suffer with fevers, malaise and anemia. The disease can also impact the infant, causing prematurity, low birth weight, congenital infection or even stillbirth.The study, which is currently enrolling patients, will be conducted at two sites -; Mboppi Baptist Hospital in Douala, Cameroon, and Baptist Hospital in Mutengene, Cameroon. As the associate director of the UAB Cameroon Health Initiative (CHI-UAB) team, Dionne-Odom will be working in tandem with in-country experts from the Cameroon Baptist Convention Health Services and faculty members from the University of Buea for the duration of the study.While Dionne-Odom is the lead investigator, an on-the-ground team in Cameroon working at four hospital facilities includes a project coordinator, four research nurses, two research assistants, a pharmacist, clinicians and administrators. This malaria project is one of several ongoing CHI-UAB global research projects focusing on improving maternal and child health.The study will enroll 310 women over a two-year period.Dionne-Odom was recently awarded the 2018 UAB Pittman Scholar Award for Excellence in Research.Source: read more